NIH-funded research R01 grant

How sublingual buprenorphine may affect mouth and dental health

Official title: Understanding the Association between Sublingual Buprenorphine and Oral Health Outcomes

Funded at University of Kentucky · NIH-11354406 · Data updated 2026-11-12

This project will compare saliva, mouth bacteria, and dental health in adults with opioid use disorder who take sublingual buprenorphine to learn whether the medicine is linked to more oral disease.

More Oral Health research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Kentucky
NIH-funded
Lab location1 site (Lexington, United States)
Project startSeptember 21, 2023
Project endAugust 31, 2028
Funding year2025
Award (this year)$625,388
NIH project number4R01DE033318-02
Project IDNIH-11354406 on NIH RePORTER

Who could benefit from this research

Could help

Adults with opioid use disorder who are currently taking or starting sublingual buprenorphine and who can attend clinic visits are the best fit for this study.

Less likely to help

People not using sublingual buprenorphine, those on other forms of MOUD exclusively, or those unable to attend follow-up visits are unlikely to benefit directly from joining.

What this research studies

If you join, the team will follow your dental health over time with regular mouth exams and questionnaires about oral hygiene and behaviors. They will collect saliva and oral swabs to measure salivary flow, pH, and inflammatory markers and will use 16S rRNA sequencing to profile mouth bacteria. The study will compare people taking sublingual buprenorphine to control groups while accounting for smoking, diet, and other lifestyle factors. Results will show whether changes in saliva or the oral microbiome explain any increased dental disease.

Why it matters

Potential benefit: If successful, the work could identify preventable causes of dental problems in people using sublingual buprenorphine and guide steps (like extra dental care) to reduce harm.

How similar studies have gone: Previous evidence linking sublingual buprenorphine to oral disease comes mostly from case reports and adverse-event summaries, so longitudinal microbiome-focused work like this is relatively novel.

Where this research is happening

  • University of Kentucky
    Lexington, United States
    Active

Researchers

  • Principal investigator: Rojas Ramirez, Marcia Vanessa — University of Kentucky
  • Study coordinator: Rojas Ramirez, Marcia Vanessa

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.